{
  "id": "chorea-evaluation",
  "title": "Chorea Evaluation",
  "version": "1.2",
  "icd10": [
    "** G25.5 (Other chorea)",
    "G25.4 (Drug-induced chorea)",
    "G10 (Huntington disease)",
    "I02.9 (Rheumatic chorea — Sydenham)",
    "G25.0 (Essential tremor — when chorea is considered)"
  ],
  "scope": "** Systematic evaluation of chorea in adults and adolescents. Covers the differential diagnosis approach to chorea including hereditary (Huntington disease, HD phenocopies), autoimmune (Sydenham, SLE, antiphospholipid syndrome), drug-induced (tardive, dopaminergic), metabolic (thyrotoxicosis, Wilson disease, hyper/hypoglycemia), vascular (post-stroke), and paraneoplastic etiologies. Includes treatment with VMAT2 inhibitors and symptomatic management. Excludes tardive dyskinesia as primary diagnosis (covered separately).",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "Essential/Core Labs (All Patients with Chorea)": [
        {
          "item": "CBC (CPT 85025)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Baseline; polycythemia vera can cause chorea; infection screen",
          "target": "Normal"
        },
        {
          "item": "CMP (CPT 80053) (electrolytes, glucose, calcium, LFTs, renal function)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Hyperglycemia/hypoglycemia, hepatic failure, uremia, electrolyte disturbances all cause chorea; Wilson disease screen (LFTs)",
          "target": "Normal glucose (70-100); normal calcium; normal LFTs; normal renal function"
        },
        {
          "item": "TSH and Free T4 (CPT 84443, 84439)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Thyrotoxicosis causes chorea; common and treatable",
          "target": "Normal TSH (0.4-4.0); normal FT4"
        },
        {
          "item": "Ceruloplasmin (CPT 82390)",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Wilson disease screen (low ceruloplasmin); must consider in ALL patients <50 with unexplained chorea",
          "target": "Normal (20-40 mg/dL); <20 mg/dL suggests Wilson"
        },
        {
          "item": "Serum copper (CPT 82525)",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Wilson disease (elevated free copper); calculate free copper from total copper and ceruloplasmin",
          "target": "Normal total copper; free copper <15 mcg/dL"
        },
        {
          "item": "ESR / CRP (CPT 85652, 86200)",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Autoimmune/inflammatory causes (SLE, Sydenham, vasculitis)",
          "target": "Normal"
        },
        {
          "item": "ANA (CPT 86235)",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "SLE-associated chorea",
          "target": "Negative"
        },
        {
          "item": "Blood glucose (fingerstick or serum)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Non-ketotic hyperglycemia is a common cause of acute hemichorea in elderly; hypoglycemia rarely causes chorea",
          "target": "Normal (70-100 mg/dL)"
        },
        {
          "item": "Medication reconciliation",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Drug-induced chorea: dopamine agonists, levodopa, stimulants, anticonvulsants (phenytoin, carbamazepine), oral contraceptives, anticholinergics",
          "target": "No offending medications"
        },
        {
          "item": "Pregnancy test (reproductive-age women)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Chorea gravidarum; oral contraceptive-related chorea",
          "target": "Negative"
        }
      ],
      "Extended Workup (Second-line)": [
        {
          "item": "Antiphospholipid antibodies (anti-cardiolipin IgG/IgM, lupus anticoagulant, anti-β2-glycoprotein I) (CPT 86146, 86147)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "Antiphospholipid syndrome: autoimmune chorea with thrombotic risk; may occur with or without SLE",
          "target": "Negative"
        },
        {
          "item": "Anti-dsDNA antibodies",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "SLE confirmation if ANA positive",
          "target": "Negative"
        },
        {
          "item": "Complement C3/C4 (CPT 86163)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "Low complement in active SLE",
          "target": "Normal"
        },
        {
          "item": "ASO titer (anti-streptolysin O) (CPT 86060)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Sydenham chorea (post-streptococcal); may be elevated",
          "target": "Normal (<200 IU/mL)"
        },
        {
          "item": "Anti-DNase B antibody",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "More sensitive than ASO for post-streptococcal etiology",
          "target": "Normal"
        },
        {
          "item": "24-hour urine copper (CPT 82016)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Wilson disease confirmation (>100 mcg/24h; >40 mcg/24h is suspicious)",
          "target": "<40 mcg/24hr"
        },
        {
          "item": "HbA1c (CPT 83036)",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "Poorly controlled diabetes causing hyperglycemic chorea",
          "target": "<5.7%"
        },
        {
          "item": "HIV antibody",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "HIV-associated chorea (basal ganglia pathology)",
          "target": "Negative"
        },
        {
          "item": "RPR/VDRL",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Neurosyphilis can cause movement disorders",
          "target": "Nonreactive"
        },
        {
          "item": "Ferritin",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Neurodegeneration with brain iron accumulation (NBIA)",
          "target": "Normal"
        },
        {
          "item": "Serum sodium",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Hyponatremia causing movement disorder (rare)",
          "target": "Normal (135-145 mEq/L)"
        },
        {
          "item": "Peripheral blood smear",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE",
          "rationale": "Acanthocytes (chorea-acanthocytosis/neuroacanthocytosis)",
          "target": "No acanthocytes"
        }
      ],
      "Rare/Specialized (Genetic and Immunologic)": [
        {
          "item": "HTT gene testing (Huntington disease CAG repeat) (CPT 81401)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Gold standard for HD diagnosis; ≥36 CAG repeats diagnostic; requires genetic counseling before ordering",
          "target": "<36 CAG repeats (normal); 36-39 = reduced penetrance; ≥40 = full penetrance"
        },
        {
          "item": "Paraneoplastic antibody panel (CRMP5, CASPR2, LGI1, NMDAR)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Paraneoplastic chorea; autoimmune encephalitis with movement disorder",
          "target": "Negative"
        },
        {
          "item": "Anti-basal ganglia antibodies",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Sydenham chorea; PANDAS-related chorea",
          "target": "Negative"
        },
        {
          "item": "Slit-lamp examination (Kayser-Fleischer rings)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Wilson disease confirmation; copper deposition in Descemet membrane",
          "target": "No KF rings"
        },
        {
          "item": "Genetic panel for HD phenocopies (C9orf72, HDL2/JPH3, SCA17, DRPLA, chorea-acanthocytosis/VPS13A, McLeod/XK)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "HD-negative chorea with family history; hereditary chorea phenocopies",
          "target": "No pathogenic variant"
        },
        {
          "item": "Benign hereditary chorea gene (NKX2-1/TITF1)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Childhood-onset non-progressive chorea with thyroid and lung abnormalities",
          "target": "No pathogenic variant"
        },
        {
          "item": "CSF analysis (cell count, protein, oligoclonal bands, cytology)",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Autoimmune/inflammatory chorea; paraneoplastic; CNS infection",
          "target": "Normal"
        }
      ]
    },
    "Imaging & Studies": {
      "Essential/First-line": [
        {
          "item": "MRI brain with/without contrast (CPT 70553)",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT",
          "timing": "All patients; priority imaging",
          "target": "Normal in early HD; caudate atrophy in established HD; T1 hyperintensity in basal ganglia (hyperglycemic chorea); signal changes in basal ganglia (Wilson, SLE, infection)",
          "contraindications": "MRI-incompatible devices"
        },
        {
          "item": "CT head without contrast",
          "ED": "STAT",
          "HOSP": "-",
          "OPD": "-",
          "ICU": "STAT",
          "timing": "ED acute onset; exclude stroke, hemorrhage; hemiballismus from subthalamic lesion",
          "target": "No acute lesion; may show caudate atrophy in HD",
          "contraindications": "None"
        }
      ],
      "Extended": [
        {
          "item": "FDG-PET brain (CPT 78608)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "HD: early caudate hypometabolism before atrophy visible on MRI",
          "target": "Normal; caudate hypometabolism suggests HD or striatal degeneration",
          "contraindications": "Pregnancy"
        },
        {
          "item": "MRA or CTA (head and neck)",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "URGENT",
          "timing": "Acute hemichorea/hemiballismus: evaluate for stroke or vascular malformation",
          "target": "Normal; infarct or vascular abnormality in subthalamic region or basal ganglia",
          "contraindications": "Contrast allergy; renal insufficiency"
        },
        {
          "item": "EEG (CPT 95816)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "ROUTINE",
          "timing": "Seizures presenting as chorea-like movements; autoimmune encephalitis; CJD",
          "target": "Normal; epileptiform activity; encephalopathic pattern",
          "contraindications": "None"
        },
        {
          "item": "Echocardiogram",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Rheumatic heart disease in Sydenham chorea; endocarditis; SLE cardiac involvement",
          "target": "Normal; valvular disease suggests rheumatic etiology",
          "contraindications": "None"
        },
        {
          "item": "MRI liver (or hepatic ultrasound)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Wilson disease: hepatic involvement; cirrhosis",
          "target": "Normal liver",
          "contraindications": "MRI-incompatible devices"
        },
        {
          "item": "Chest CT",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Paraneoplastic evaluation; malignancy screen",
          "target": "No malignancy",
          "contraindications": "Contrast allergy"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "DaTscan (I-123 ioflupane SPECT)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Striatal dopamine transporter; may differentiate degenerative from non-degenerative chorea",
          "target": "Normal in autoimmune/drug-induced chorea; reduced in HD and neurodegenerative causes",
          "contraindications": "Iodine hypersensitivity"
        },
        {
          "item": "Neuropsychological testing",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Cognitive profile in suspected HD; executive dysfunction; psychiatric evaluation",
          "target": "Normal cognition; abnormal = supports neurodegenerative etiology",
          "contraindications": "None"
        },
        {
          "item": "MRI brain volumetrics",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Quantify caudate volume; track progression in HD",
          "target": "Normal; caudate volume loss supports HD",
          "contraindications": "MRI-incompatible devices"
        }
      ]
    },
    "Treatment": {
      "Acute/Emergent": [
        {
          "item": "Haloperidol",
          "route": "IV/IM/PO",
          "indication": "Acute severe chorea/ballism causing injury or functional impairment; fastest onset of chorea suppression",
          "dosing": {
            "doseOptions": [
              {
                "text": "2 mg",
                "orderSentence": "Haloperidol 2 mg IV/IM"
              },
              {
                "text": "5 mg",
                "orderSentence": "Haloperidol 5 mg IV/IM"
              }
            ],
            "route": "IV/IM",
            "instructions": "2-5 mg IM/IV for acute management; may repeat q30-60 min; max 20 mg/day; transition to oral when stable",
            "orderSentence": "Haloperidol 2 mg IV/IM"
          },
          "contraindications": "Parkinson disease; Lewy body dementia; severe QT prolongation; neuroleptic malignant syndrome history",
          "monitoring": "QTc; EPS/dystonia; sedation; BP; NMS signs (rigidity, fever, CK)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Insulin + IV dextrose (for hyperglycemic chorea)",
          "route": "IV",
          "indication": "Non-ketotic hyperglycemic hemichorea/hemiballismus; correct hyperglycemia",
          "dosing": {
            "doseOptions": [
              {
                "text": "Per protocol",
                "orderSentence": "Insulin + IV dextrose (for hyperglycemic chorea) Per protocol IV"
              }
            ],
            "route": "IV",
            "instructions": "Treat underlying hyperglycemia aggressively; chorea typically resolves with glucose normalization over hours to days; insulin drip if severe",
            "orderSentence": "Insulin + IV dextrose (for hyperglycemic chorea) Per protocol IV"
          },
          "contraindications": "Hypoglycemia",
          "monitoring": "Blood glucose q1h; electrolytes; mental status; chorea severity",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Valproic acid (IV)",
          "route": "IV",
          "indication": "Acute severe chorea refractory to neuroleptics; especially if seizure concern",
          "dosing": {
            "doseOptions": [
              {
                "text": "20 mg/kg load",
                "orderSentence": "Valproic acid (IV) 20 mg/kg load IV"
              },
              {
                "text": "500 mg q8h",
                "orderSentence": "Valproic acid (IV) 500 mg q8h IV"
              }
            ],
            "route": "IV",
            "instructions": "Loading dose 20 mg/kg IV (max 1500 mg); then 500 mg IV q8h; therapeutic level 50-100 mcg/mL",
            "orderSentence": "Valproic acid (IV) 20 mg/kg load IV"
          },
          "contraindications": "Hepatic disease; pregnancy; urea cycle disorders",
          "monitoring": "Drug levels; LFTs; CBC; ammonia",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT"
        }
      ],
      "Symptomatic Treatments (Chorea Suppression)": [
        {
          "item": "Deutetrabenazine (Austedo)",
          "route": "PO",
          "indication": "Chorea associated with Huntington disease (FDA-approved); tardive dyskinesia; preferred VMAT2 inhibitor due to lower depression/suicidality risk",
          "dosing": {
            "doseOptions": [
              {
                "text": "6 mg daily",
                "orderSentence": "Deutetrabenazine (Austedo) 6 mg daily PO"
              },
              {
                "text": "6 mg BID",
                "orderSentence": "Deutetrabenazine (Austedo) 6 mg BID PO"
              },
              {
                "text": "12 mg BID",
                "orderSentence": "Deutetrabenazine (Austedo) 12 mg BID PO"
              },
              {
                "text": "24 mg BID",
                "orderSentence": "Deutetrabenazine (Austedo) 24 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 6 mg daily; increase by 6 mg/day q1wk; max 48 mg/day divided BID; take with food; CYP2D6 poor metabolizers: max 36 mg/day",
            "orderSentence": "Deutetrabenazine (Austedo) 6 mg daily PO"
          },
          "contraindications": "Active suicidality; untreated or inadequately treated depression; concurrent MAOIs; concurrent tetrabenazine or reserpine; hepatic impairment",
          "monitoring": "Depression/suicidality (screen with PHQ-9 each visit); akathisia; parkinsonism; dysphagia; QTc if risk factors; CYP2D6 genotyping recommended",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Tetrabenazine (Xenazine)",
          "route": "PO",
          "indication": "Chorea associated with HD; other causes of chorea; original VMAT2 inhibitor",
          "dosing": {
            "doseOptions": [
              {
                "text": "12.5 mg daily",
                "orderSentence": "Tetrabenazine (Xenazine) 12.5 mg daily PO"
              },
              {
                "text": "12.5 mg BID",
                "orderSentence": "Tetrabenazine (Xenazine) 12.5 mg BID PO"
              },
              {
                "text": "25 mg BID",
                "orderSentence": "Tetrabenazine (Xenazine) 25 mg BID PO"
              },
              {
                "text": "25 mg TID",
                "orderSentence": "Tetrabenazine (Xenazine) 25 mg TID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 12.5 mg daily; increase by 12.5 mg q1wk; max 75-100 mg/day divided TID; CYP2D6 poor metabolizers: max 50 mg/day",
            "orderSentence": "Tetrabenazine (Xenazine) 12.5 mg daily PO"
          },
          "contraindications": "Active suicidality; untreated depression; concurrent MAOIs; hepatic impairment",
          "monitoring": "Depression/suicidality (BLACK BOX WARNING); akathisia; parkinsonism; sedation; dysphagia; CYP2D6 genotyping before exceeding 50 mg/day",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Valbenazine (Ingrezza)",
          "route": "PO",
          "indication": "Tardive dyskinesia (FDA-approved); off-label for other causes of chorea",
          "dosing": {
            "doseOptions": [
              {
                "text": "40 mg daily",
                "orderSentence": "Valbenazine (Ingrezza) 40 mg daily PO"
              },
              {
                "text": "80 mg daily",
                "orderSentence": "Valbenazine (Ingrezza) 80 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 40 mg daily; increase to 80 mg daily after 1 week; once-daily dosing advantageous",
            "orderSentence": "Valbenazine (Ingrezza) 40 mg daily PO"
          },
          "contraindications": "Active suicidality; concurrent MAOIs; severe hepatic impairment; concurrent strong CYP3A4 inhibitors (reduces to 40 mg)",
          "monitoring": "Depression/suicidality; akathisia; somnolence; QTc",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Risperidone",
          "route": "PO",
          "indication": "Chorea suppression with antipsychotic effect; useful if psychiatric symptoms coexist",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.5 mg daily",
                "orderSentence": "Risperidone 0.5 mg daily PO"
              },
              {
                "text": "1 mg BID",
                "orderSentence": "Risperidone 1 mg BID PO"
              },
              {
                "text": "2 mg BID",
                "orderSentence": "Risperidone 2 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 0.5 mg daily; titrate by 0.5-1 mg q1wk; max 6 mg/day; lower EPS risk than haloperidol",
            "orderSentence": "Risperidone 0.5 mg daily PO"
          },
          "contraindications": "Dementia-related psychosis (FDA black box); QT prolongation; Parkinson disease",
          "monitoring": "Metabolic (glucose, lipids, weight); EPS; prolactin; QTc; NMS",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Olanzapine",
          "route": "PO",
          "indication": "Chorea with behavioral disturbance; sedating properties may be beneficial",
          "dosing": {
            "doseOptions": [
              {
                "text": "2.5 mg daily",
                "orderSentence": "Olanzapine 2.5 mg daily PO"
              },
              {
                "text": "5 mg daily",
                "orderSentence": "Olanzapine 5 mg daily PO"
              },
              {
                "text": "10 mg daily",
                "orderSentence": "Olanzapine 10 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 2.5-5 mg daily; titrate by 2.5-5 mg q1wk; max 20 mg/day",
            "orderSentence": "Olanzapine 2.5 mg daily PO"
          },
          "contraindications": "Dementia-related psychosis (FDA black box); diabetes; metabolic syndrome",
          "monitoring": "Weight; glucose; lipids; sedation; metabolic monitoring q3mo",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Clonazepam",
          "route": "PO",
          "indication": "Mild chorea; chorea with anxiety component; adjunct therapy",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.25 mg BID",
                "orderSentence": "Clonazepam 0.25 mg BID PO"
              },
              {
                "text": "0.5 mg BID",
                "orderSentence": "Clonazepam 0.5 mg BID PO"
              },
              {
                "text": "1 mg BID",
                "orderSentence": "Clonazepam 1 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 0.25-0.5 mg BID; titrate by 0.5 mg q3-7d; max 4 mg/day",
            "orderSentence": "Clonazepam 0.25 mg BID PO"
          },
          "contraindications": "Severe respiratory insufficiency; severe hepatic impairment; acute narrow-angle glaucoma",
          "monitoring": "Sedation; fall risk; cognitive worsening; respiratory depression; dependence",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Amantadine",
          "route": "PO",
          "indication": "Mild chorea; fewer side effects than dopamine-depleting agents; useful in HD",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg daily",
                "orderSentence": "Amantadine 100 mg daily PO"
              },
              {
                "text": "100 mg BID",
                "orderSentence": "Amantadine 100 mg BID PO"
              },
              {
                "text": "200 mg BID",
                "orderSentence": "Amantadine 200 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 100 mg daily; increase to 100 mg BID; max 400 mg/day; livedo reticularis may occur",
            "orderSentence": "Amantadine 100 mg daily PO"
          },
          "contraindications": "Severe renal impairment (dose adjust); end-stage renal disease on dialysis",
          "monitoring": "Renal function; livedo reticularis; hallucinations; insomnia; ankle edema",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Citalopram",
          "route": "PO",
          "indication": "Depression in HD; first-line SSRI for mood disturbance in chorea patients",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg daily",
                "orderSentence": "Citalopram 10 mg daily PO"
              },
              {
                "text": "20 mg daily",
                "orderSentence": "Citalopram 20 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 10 mg daily; increase to 20 mg after 1 week if tolerated; max 20 mg/day (QTc risk at higher doses); onset of effect 2-4 weeks",
            "orderSentence": "Citalopram 10 mg daily PO"
          },
          "contraindications": "Concurrent MAOIs; QTc >500 ms; concurrent pimozide",
          "monitoring": "QTc at baseline and after dose change; suicidality (first 2 weeks); serotonin syndrome; hyponatremia in elderly",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Sertraline",
          "route": "PO",
          "indication": "Depression and anxiety in HD; alternative SSRI; also treats irritability and obsessive features",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg daily",
                "orderSentence": "Sertraline 25 mg daily PO"
              },
              {
                "text": "50 mg daily",
                "orderSentence": "Sertraline 50 mg daily PO"
              },
              {
                "text": "100 mg daily",
                "orderSentence": "Sertraline 100 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25 mg daily; increase by 25-50 mg q1-2wk; target 50-200 mg/day; max 200 mg/day",
            "orderSentence": "Sertraline 25 mg daily PO"
          },
          "contraindications": "Concurrent MAOIs; concurrent pimozide",
          "monitoring": "Suicidality (first 2 weeks); GI side effects; serotonin syndrome; hyponatremia",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Mirtazapine",
          "route": "PO",
          "indication": "Depression with insomnia and weight loss in HD; dual benefit of appetite stimulation and sleep improvement",
          "dosing": {
            "doseOptions": [
              {
                "text": "7.5 mg qHS",
                "orderSentence": "Mirtazapine 7.5 mg qHS PO"
              },
              {
                "text": "15 mg qHS",
                "orderSentence": "Mirtazapine 15 mg qHS PO"
              },
              {
                "text": "30 mg qHS",
                "orderSentence": "Mirtazapine 30 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 7.5-15 mg qHS; increase by 15 mg q1-2wk; max 45 mg/day; lower doses more sedating",
            "orderSentence": "Mirtazapine 7.5 mg qHS PO"
          },
          "contraindications": "Concurrent MAOIs; severe hepatic impairment",
          "monitoring": "Sedation; weight gain (beneficial in HD); lipid panel; CBC (rare agranulocytosis)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Quetiapine",
          "route": "PO",
          "indication": "Irritability, agitation, psychosis, and insomnia in HD; low-dose for sleep, higher dose for psychosis",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg qHS",
                "orderSentence": "Quetiapine 25 mg qHS PO"
              },
              {
                "text": "50 mg BID",
                "orderSentence": "Quetiapine 50 mg BID PO"
              },
              {
                "text": "150 mg BID",
                "orderSentence": "Quetiapine 150 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25 mg qHS; titrate by 25-50 mg/day q3-5d; target 50-300 mg/day for behavior; max 600 mg/day for psychosis",
            "orderSentence": "Quetiapine 25 mg qHS PO"
          },
          "contraindications": "Dementia-related psychosis (FDA black box); diabetes; severe hepatic impairment",
          "monitoring": "Weight; fasting glucose; lipids; sedation; QTc; EPS; metabolic monitoring q3mo",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Modafinil",
          "route": "PO",
          "indication": "Fatigue and excessive daytime sleepiness in HD; apathy; cognitive slowing",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg daily",
                "orderSentence": "Modafinil 100 mg daily PO"
              },
              {
                "text": "200 mg daily",
                "orderSentence": "Modafinil 200 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 100 mg daily in AM; increase to 200 mg daily after 1 week if needed; max 200 mg/day; avoid afternoon dosing",
            "orderSentence": "Modafinil 100 mg daily PO"
          },
          "contraindications": "Severe hepatic impairment; hypersensitivity; concurrent cyclosporine",
          "monitoring": "BP; HR; sleep quality; mood (can worsen anxiety); rash (discontinue if occurs)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Trazodone",
          "route": "PO",
          "indication": "Insomnia in HD; sleep disturbance; mild anxiolytic effect",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg qHS",
                "orderSentence": "Trazodone 25 mg qHS PO"
              },
              {
                "text": "50 mg qHS",
                "orderSentence": "Trazodone 50 mg qHS PO"
              },
              {
                "text": "100 mg qHS",
                "orderSentence": "Trazodone 100 mg qHS PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25-50 mg qHS; increase by 25-50 mg q3-5d; max 150 mg qHS for sleep",
            "orderSentence": "Trazodone 25 mg qHS PO"
          },
          "contraindications": "Concurrent MAOIs; severe hepatic impairment",
          "monitoring": "Sedation; orthostatic hypotension; priapism (rare); serotonin syndrome if combined with SSRIs",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Valproic acid (oral)",
          "route": "PO",
          "indication": "Irritability and aggression in HD; mood stabilization; adjunctive chorea suppression",
          "dosing": {
            "doseOptions": [
              {
                "text": "250 mg BID",
                "orderSentence": "Valproic acid (oral) 250 mg BID PO"
              },
              {
                "text": "500 mg BID",
                "orderSentence": "Valproic acid (oral) 500 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 250 mg BID; titrate to therapeutic level 50-100 mcg/mL; max 60 mg/kg/day",
            "orderSentence": "Valproic acid (oral) 250 mg BID PO"
          },
          "contraindications": "Hepatic disease; pregnancy (teratogenic); urea cycle disorders",
          "monitoring": "Drug levels; LFTs; CBC; ammonia; weight; pancreatitis symptoms",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Maintenance/Prophylaxis": [
        {
          "item": "Penicillin V (secondary prophylaxis)",
          "route": "PO",
          "indication": "Sydenham chorea: secondary streptococcal prophylaxis to prevent rheumatic heart disease recurrence",
          "dosing": {
            "doseOptions": [
              {
                "text": "250 mg BID",
                "orderSentence": "Penicillin V (secondary prophylaxis) 250 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "250 mg PO BID continuously; duration until age 21 or 10 years post-episode (whichever longer); lifelong if rheumatic heart disease",
            "orderSentence": "Penicillin V (secondary prophylaxis) 250 mg BID PO"
          },
          "contraindications": "Penicillin allergy",
          "monitoring": "Adherence; recurrence of chorea; echocardiogram for rheumatic heart disease q1-2 years",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Penicillin G benzathine (secondary prophylaxis)",
          "route": "IM",
          "indication": "Sydenham chorea: IM alternative for patients with adherence concerns",
          "dosing": {
            "doseOptions": [
              {
                "text": "1.2 million units q4wk",
                "orderSentence": "Penicillin G benzathine (secondary prophylaxis) 1.2 million units q4wk IM"
              }
            ],
            "route": "IM",
            "instructions": "1.2 million units IM q4 weeks (q3 weeks in high-risk populations); duration per rheumatic fever guidelines",
            "orderSentence": "Penicillin G benzathine (secondary prophylaxis) 1.2 million units q4wk IM"
          },
          "contraindications": "Penicillin allergy",
          "monitoring": "Injection site reactions; adherence; echocardiogram follow-up",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Zinc acetate (Wilson disease maintenance)",
          "route": "PO",
          "indication": "Wilson disease: maintenance therapy after initial chelation; blocks intestinal copper absorption",
          "dosing": {
            "doseOptions": [
              {
                "text": "50 mg TID",
                "orderSentence": "Zinc acetate (Wilson disease maintenance) 50 mg TID PO"
              }
            ],
            "route": "PO",
            "instructions": "50 mg elemental zinc TID; take between meals (1 hour before or 2 hours after); separate from chelation therapy by 2 hours",
            "orderSentence": "Zinc acetate (Wilson disease maintenance) 50 mg TID PO"
          },
          "contraindications": "GI intolerance",
          "monitoring": "24-hr urine copper; serum zinc; 24-hr urine zinc; GI side effects",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Anticoagulation (warfarin or DOAC)",
          "route": "PO",
          "indication": "Antiphospholipid syndrome-associated chorea with thrombotic risk; long-term thromboprophylaxis",
          "dosing": {
            "doseOptions": [
              {
                "text": "Per APS guidelines",
                "orderSentence": "Anticoagulation (warfarin or DOAC) Per APS guidelines PO"
              }
            ],
            "route": "PO",
            "instructions": "Warfarin (target INR 2-3) or DOAC per rheumatology guidance; lifelong if APS with thrombosis",
            "orderSentence": "Anticoagulation (warfarin or DOAC) Per APS guidelines PO"
          },
          "contraindications": "Active bleeding; coagulopathy; recent surgery",
          "monitoring": "INR (warfarin) q2-4wk; renal function (DOAC); bleeding signs; fall risk assessment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Disease-Modifying/Etiology-Specific Treatment": [
        {
          "item": "Penicillin V or Amoxicillin (acute treatment)",
          "route": "PO",
          "indication": "Sydenham chorea: eradicate active streptococcal infection",
          "dosing": {
            "doseOptions": [
              {
                "text": "250 mg BID",
                "orderSentence": "Penicillin V or Amoxicillin (acute treatment) 250 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Penicillin V 250 mg BID x 10 days or Amoxicillin 250 mg BID x 10 days; full course to eradicate GAS; followed by secondary prophylaxis (see 3C)",
            "orderSentence": "Penicillin V or Amoxicillin (acute treatment) 250 mg BID PO"
          },
          "pretreatment": "ASO titer; throat culture",
          "contraindications": "Penicillin allergy",
          "monitoring": "Adherence; symptom resolution; transition to secondary prophylaxis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Prednisone",
          "route": "PO",
          "indication": "Autoimmune chorea (SLE, antiphospholipid syndrome, Sydenham); immune-mediated chorea refractory to supportive care",
          "dosing": {
            "doseOptions": [
              {
                "text": "1 mg/kg daily",
                "orderSentence": "Prednisone 1 mg/kg daily PO"
              },
              {
                "text": "60 mg daily",
                "orderSentence": "Prednisone 60 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "1 mg/kg/day (max 60 mg) for 2-4 weeks; then taper over 4-8 weeks; for Sydenham, consider if severe or disabling",
            "orderSentence": "Prednisone 1 mg/kg daily PO"
          },
          "pretreatment": "Baseline glucose; TB screening; hepatitis B status",
          "contraindications": "Active untreated infection; uncontrolled diabetes; active GI bleed",
          "monitoring": "Blood glucose; BP; mood; bone density; GI protection; weight",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "IVIG",
          "route": "IV",
          "indication": "Severe autoimmune chorea (Sydenham, SLE) refractory to corticosteroids; paraneoplastic chorea",
          "dosing": {
            "doseOptions": [
              {
                "text": "2 g/kg total",
                "orderSentence": "IVIG 2 g/kg total IV"
              }
            ],
            "route": "IV",
            "instructions": "0.4 g/kg/day IV for 5 days or 1 g/kg/day for 2 days; may repeat q4wk if relapsing",
            "orderSentence": "IVIG 2 g/kg total IV"
          },
          "pretreatment": "IgA levels; renal function",
          "contraindications": "IgA deficiency (anaphylaxis risk); severe renal impairment; thrombotic risk",
          "monitoring": "Renal function; headache (aseptic meningitis); thrombotic events; hemolysis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Plasma exchange (PLEX)",
          "route": "IV",
          "indication": "Severe refractory autoimmune chorea; paraneoplastic chorea; rapid onset of action needed",
          "dosing": {
            "doseOptions": [
              {
                "text": "5-7 exchanges",
                "orderSentence": "Plasma exchange (PLEX) 5-7 exchanges IV"
              }
            ],
            "route": "IV",
            "instructions": "5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange",
            "orderSentence": "Plasma exchange (PLEX) 5-7 exchanges IV"
          },
          "pretreatment": "Central venous access",
          "contraindications": "Coagulopathy; hemodynamic instability; active infection",
          "monitoring": "Electrolytes (calcium, potassium); coagulation studies; hemodynamic status; line complications",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "D-penicillamine",
          "route": "PO",
          "indication": "Wilson disease: first-line copper chelation therapy",
          "dosing": {
            "doseOptions": [
              {
                "text": "250 mg daily",
                "orderSentence": "D-penicillamine 250 mg daily PO"
              },
              {
                "text": "500 mg BID",
                "orderSentence": "D-penicillamine 500 mg BID PO"
              },
              {
                "text": "750 mg BID",
                "orderSentence": "D-penicillamine 750 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 250 mg daily; increase by 250 mg q4-7d; target 1000-1500 mg/day divided BID-TID; take 1 hour before meals",
            "orderSentence": "D-penicillamine 250 mg daily PO"
          },
          "pretreatment": "24-hr urine copper; LFTs; CBC; urinalysis",
          "contraindications": "Penicillin allergy (cross-reaction); renal impairment; lupus-like syndrome history; cytopenias",
          "monitoring": "CBC q2wk x 3 months then monthly; urinalysis (proteinuria); 24-hr urine copper; LFTs; free serum copper; neurologic worsening first 6 months possible",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Trientine (Syprine)",
          "route": "PO",
          "indication": "Wilson disease: copper chelation; D-penicillamine intolerant patients",
          "dosing": {
            "doseOptions": [
              {
                "text": "250 mg TID",
                "orderSentence": "Trientine (Syprine) 250 mg TID PO"
              },
              {
                "text": "500 mg TID",
                "orderSentence": "Trientine (Syprine) 500 mg TID PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 250 mg TID; target 750-1500 mg/day divided TID; take 1 hour before or 2 hours after meals; fewer side effects than D-penicillamine",
            "orderSentence": "Trientine (Syprine) 250 mg TID PO"
          },
          "pretreatment": "24-hr urine copper; LFTs; CBC; urinalysis",
          "contraindications": "Caution with iron supplements (separate by 2 hours)",
          "monitoring": "CBC; LFTs; urinalysis monthly initially then q3mo; 24-hr urine copper",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    },
    "Other Recommendations": {
      "Referrals & Consults": [
        {
          "item": "Neurology (movement disorders specialist) for diagnostic classification, VMAT2 inhibitor management, and long-term chorea suppression",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Genetic counseling BEFORE Huntington disease gene testing (mandatory; informed consent for implications for family, insurance, and reproductive planning)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Rheumatology if autoimmune chorea suspected (SLE, antiphospholipid syndrome) for systemic disease management",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Hepatology if Wilson disease diagnosed for liver disease management and transplant evaluation if needed",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Cardiology for echocardiogram if Sydenham chorea or rheumatic fever suspected (rheumatic heart disease screening)",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Psychiatry for management of depression, psychosis, irritability, and suicidality especially in Huntington disease",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Endocrinology if hyperglycemic chorea for long-term diabetes management and glucose optimization",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Physical therapy for balance, gait, and fall prevention; adaptive movement strategies",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Occupational therapy for adaptive equipment, home safety assessment, and activities of daily living support",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Speech therapy for dysarthria and dysphagia assessment, especially in HD; swallowing evaluation before discharge",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Oncology if paraneoplastic chorea diagnosed (CRMP5, CASPR2 antibodies) for malignancy workup and treatment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Social work for care coordination, advance directive planning, disability resources, and family support in HD",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Patient Instructions": [
        {
          "item": "Report new or worsening depression, suicidal thoughts, or mood changes immediately while on VMAT2 inhibitors (tetrabenazine has BLACK BOX WARNING for suicidality)",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Use fall precautions at home and in hospital; chorea increases fall risk especially with gait involvement; use handrails, non-slip footwear",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Return to ED if chorea suddenly worsens, new weakness develops, speech/swallowing difficulty appears, or signs of stroke occur",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Do not stop chorea medications abruptly; sudden withdrawal of dopamine-blocking agents can cause withdrawal dyskinesia or rebound chorea",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Genetic counseling is mandatory before and after Huntington disease testing due to implications for family members, insurance, and reproductive planning",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Take VMAT2 inhibitors with food for better absorption (deutetrabenazine requires food); report any difficulty swallowing pills",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Maintain adequate fluid and caloric intake; HD patients have increased metabolic demand due to involuntary movements and are at risk for malnutrition",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Avoid driving or operating heavy machinery until chorea severity is assessed and medication side effects (sedation, parkinsonism) are stable",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Carry a medical alert identification if diagnosed with Huntington disease or if on anticoagulation for antiphospholipid syndrome",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Report new involuntary movements, stiffness, tremor, or restlessness that could indicate medication side effects (EPS, parkinsonism, akathisia)",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        }
      ],
      "Lifestyle & Prevention": [
        {
          "item": "Home safety evaluation to remove sharp edges, pad furniture, and reduce fall hazards given involuntary movements",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Caloric intake monitoring in HD (chorea increases metabolic demand by 500-1000 kcal/day; weight loss is common and associated with worse outcomes)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Advance care planning early in HD course while decision-making capacity is preserved; designate healthcare proxy",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Support groups: Huntington's Disease Society of America (HDSA) for patients and families with HD; local and online resources",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Avoid medications that worsen chorea: dopamine agonists, levodopa, stimulants, anticholinergics (review all medications at each visit)",
          "ED": "ROUTINE",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Regular aerobic exercise (adapted to chorea severity) to improve mood, endurance, and cardiovascular health; supervised physical activity preferred",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Stress management with relaxation techniques as stress and fatigue exacerbate chorea severity",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Adequate sleep hygiene; sleep deprivation worsens chorea and cognitive function in HD",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Limit alcohol use; alcohol interacts with benzodiazepines and VMAT2 inhibitors; Wilson disease patients must avoid alcohol",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        }
      ]
    }
  },
  "differential": [
    {
      "diagnosis": "Huntington disease",
      "features": "Family history (autosomal dominant); progressive chorea + cognitive decline + psychiatric symptoms; caudate atrophy on MRI",
      "tests": "HTT gene testing (≥36 CAG repeats); MRI (caudate atrophy); family history"
    },
    {
      "diagnosis": "Tardive dyskinesia",
      "features": "History of dopamine receptor blocking agent exposure; orofacial predominance (lip-smacking, tongue movements); may involve limbs",
      "tests": "Medication history (antipsychotics, metoclopramide); AIMS scale; onset after ≥3 months of neuroleptic exposure"
    },
    {
      "diagnosis": "Sydenham chorea",
      "features": "Children/adolescents; preceded by streptococcal infection; self-limiting (months); associated with rheumatic fever",
      "tests": "ASO titer; anti-DNase B; echocardiogram (rheumatic heart disease); Jones criteria"
    },
    {
      "diagnosis": "SLE chorea",
      "features": "Young women; other SLE features (rash, arthritis, nephritis); antiphospholipid antibodies often positive",
      "tests": "ANA; anti-dsDNA; antiphospholipid antibodies; complement C3/C4; lupus diagnostic criteria"
    },
    {
      "diagnosis": "Antiphospholipid syndrome chorea",
      "features": "Chorea with thrombotic events; may occur without SLE; lupus anticoagulant positive",
      "tests": "Antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin, anti-β2GP1); thrombotic history"
    },
    {
      "diagnosis": "Wilson disease",
      "features": "Age <50; liver disease; psychiatric symptoms; Kayser-Fleischer rings; dystonia often coexists",
      "tests": "Ceruloplasmin (low); 24-hr urine copper (elevated); slit-lamp exam (KF rings); genetic testing (ATP7B)"
    },
    {
      "diagnosis": "Non-ketotic hyperglycemic chorea",
      "features": "Elderly; acute hemichorea/hemiballismus; very high blood glucose; T1 hyperintensity in contralateral putamen on MRI",
      "tests": "Blood glucose (often >400 mg/dL); MRI (T1 hyperintensity in basal ganglia); HbA1c; resolves with glucose normalization"
    },
    {
      "diagnosis": "Post-stroke chorea/hemiballismus",
      "features": "Acute onset; hemiballismus or hemichorea; contralateral subthalamic or basal ganglia lesion",
      "tests": "MRI brain (infarct in subthalamic nucleus, striatum, or thalamus); vascular risk factors"
    },
    {
      "diagnosis": "Drug-induced chorea (non-tardive)",
      "features": "Temporal relationship to medication (levodopa, dopamine agonists, stimulants, anticonvulsants, OCP)",
      "tests": "Medication reconciliation; resolution with drug discontinuation or dose reduction"
    },
    {
      "diagnosis": "Paraneoplastic chorea",
      "features": "Subacute onset; weight loss; smoking history; CRMP5 or CASPR2 antibodies; may have other neurologic features",
      "tests": "Paraneoplastic antibody panel; CT chest/abdomen/pelvis; PET/CT"
    },
    {
      "diagnosis": "Chorea-acanthocytosis (neuroacanthocytosis)",
      "features": "Orofacial chorea with lip/tongue biting; feeding dystonia; seizures; elevated CK; acanthocytes on blood smear",
      "tests": "Peripheral blood smear (acanthocytes); CK (elevated); VPS13A gene testing"
    },
    {
      "diagnosis": "Benign hereditary chorea",
      "features": "Childhood onset; non-progressive; thyroid and pulmonary abnormalities may be present; NKX2-1 mutations",
      "tests": "NKX2-1/TITF1 gene testing; thyroid function; chest imaging; non-progressive course"
    },
    {
      "diagnosis": "Polycythemia vera",
      "features": "Chorea as rare manifestation; erythrocytosis; splenomegaly; JAK2 mutation",
      "tests": "CBC (elevated Hgb/Hct); JAK2 V617F mutation; EPO level"
    }
  ],
  "evidence": [
    {
      "recommendation": "Deutetrabenazine reduces chorea in Huntington disease (FIRST-HD and ARC-HD trials)",
      "evidenceLevel": "Class I, Level A",
      "source": "[Frank S et al. JAMA Neurol 2016](https://pubmed.ncbi.nlm.nih.gov/27400766/)"
    },
    {
      "recommendation": "Tetrabenazine reduces chorea in Huntington disease (TETRA-HD trial)",
      "evidenceLevel": "Class I, Level A",
      "source": "[Huntington Study Group. Neurology 2006](https://pubmed.ncbi.nlm.nih.gov/16894106/)"
    },
    {
      "recommendation": "VMAT2 inhibitors: tetrabenazine BLACK BOX WARNING for depression and suicidality",
      "evidenceLevel": "FDA Labeling",
      "source": "[FDA Xenazine Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf)"
    },
    {
      "recommendation": "Non-ketotic hyperglycemic hemichorea: glucose correction resolves symptoms",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Oh SH et al. Diabetes Care 2002](https://pubmed.ncbi.nlm.nih.gov/12351497/)"
    },
    {
      "recommendation": "AAN practice guideline on pharmacologic treatment of chorea in HD",
      "evidenceLevel": "Guideline",
      "source": "[Armstrong MJ, Miyasaki JM. Neurology 2012](https://pubmed.ncbi.nlm.nih.gov/22815558/)"
    },
    {
      "recommendation": "Wilson disease diagnosis and treatment",
      "evidenceLevel": "Guideline",
      "source": "[EASL Clinical Practice Guidelines. J Hepatol 2012](https://pubmed.ncbi.nlm.nih.gov/22340672/)"
    },
    {
      "recommendation": "Sydenham chorea management per rheumatic fever guidelines",
      "evidenceLevel": "Guideline",
      "source": "[Gewitz MH et al. Circulation 2015](https://pubmed.ncbi.nlm.nih.gov/25877495/)"
    },
    {
      "recommendation": "Antiphospholipid syndrome-associated chorea responds to immunosuppression and anticoagulation",
      "evidenceLevel": "Class IIa, Level C",
      "source": "[Cervera R et al. Medicine 1997](https://pubmed.ncbi.nlm.nih.gov/9065650/)"
    }
  ],
  "monitoring": [
    {
      "item": "Chorea severity (UHDRS Total Motor Score or clinical assessment)",
      "frequency": "Each visit",
      "action": "Adjust VMAT2 inhibitor dose; add/change agent",
      "ED": "ROUTINE",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "Depression screening (PHQ-9)",
      "frequency": "Each visit; mandatory on VMAT2 inhibitors",
      "action": "Reduce VMAT2 inhibitor if new depression; psychiatry referral; SSRI if needed",
      "ED": "ROUTINE",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "Swallowing function",
      "frequency": "Q6 months in HD; each visit if symptomatic",
      "action": "Speech therapy evaluation; diet modification; aspiration precautions",
      "ED": "ROUTINE",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "Weight / nutritional status",
      "frequency": "Each visit",
      "action": "Dietary supplementation; increase caloric intake (HD patients burn extra calories from chorea)",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "Cognitive function (MoCA or MMSE)",
      "frequency": "Q6-12 months",
      "action": "Neuropsychological reassessment; care planning",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Blood glucose (if hyperglycemic chorea)",
      "frequency": "Q1-4h during acute; then per DM management",
      "action": "Insulin adjustment; endocrinology",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Liver function (if on Wilson disease treatment)",
      "frequency": "Q2-4wk initially; then Q3 months",
      "action": "Adjust chelation dose; hepatology evaluation",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "QTc (if on antipsychotics)",
      "frequency": "Baseline; after dose changes",
      "action": "Reduce dose; switch agent; cardiology if prolonged",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    }
  ],
  "disposition": [
    {
      "disposition": "Discharge from ED",
      "criteria": "Mild chorea without acute metabolic cause; stable hemodynamics; no swallowing risk; outpatient neurology follow-up arranged; offending medication identified and addressed"
    },
    {
      "disposition": "Admit to floor",
      "criteria": "New-onset severe chorea requiring urgent workup; hyperglycemic chorea requiring insulin management; suspected autoimmune or paraneoplastic chorea needing expedited workup; hemiballismus from acute stroke; Wilson disease with hepatic decompensation"
    },
    {
      "disposition": "Admit to ICU",
      "criteria": "Severe ballismus causing injury or exhaustion; chorea with aspiration pneumonia and respiratory failure; status epilepticus; Wilson disease with acute liver failure"
    },
    {
      "disposition": "Outpatient follow-up (movement disorders)",
      "criteria": "All patients with chronic chorea: q3-6 months; Huntington disease: multidisciplinary HD clinic q3-6 months; medication titration: q2-4 weeks"
    },
    {
      "disposition": "Genetic counseling",
      "criteria": "Required BEFORE Huntington gene testing; post-test counseling for positive results"
    }
  ]
}